Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)

Impact · against what's priced in

Abivax is poised for significant upside as new safety data suggests Obefezimod can be used in earlier treatment lines, expanding its total addressable market. The combination of a near-certain regulatory success probability (95%) and potential expansion into Crohn's disease creates a clear catalyst for price appreciation toward the $140 target.

ABVX+0.80

No priced-in read yet

In context

The shift toward first-line treatment potential and a 95% probability of success significantly increases the asset's valuation and expands the target patient population beyond refractory cases.

Read from the article alone

• biotech▲2%
• healthcare
• pharmaceuticals
• ABVX
• clinical trials
• crohns disease
• drug pipeline
• phase 3
• ulcerative colitis